Filing Flows › Veracyte (VCYT) › Biopharmaceutical and other revenue revenue
Veracyte (VCYT) Biopharmaceutical and other revenue revenue by quarter
Veracyte's Biopharmaceutical and other revenue revenue was $709K in Q3 2026 (third quarter 2026), -12% from Q2 2026. Over the last 6 quarters it ranged from $301K (Q1 2026) to $3.6M (Q1 2025).
| Quarter | Biopharmaceutical and other revenue revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $709K | -12% | -13% |
| Q2 2026 | $802K | +166% | — |
| Q1 2026 | $301K | -69% | -92% |
| Q4 2025 | $962K | +18% | — |
| Q3 2025 | $815K | -77% | — |
| Q1 2025 | $3.6M | — | — |
Q3 2026 at a glance
Veracyte, Q3 2026: revenue $152M (+15% year over year), operating margin 10.9%, net earnings $31.5M, operating cash flow $40.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is Veracyte's Biopharmaceutical and other revenue revenue?
Veracyte's Biopharmaceutical and other revenue revenue was $709K in Q3 2026 (third quarter 2026), -12% from Q2 2026.
How has Veracyte's Biopharmaceutical and other revenue revenue changed?
Over the last 6 quarters it ranged from $301K (Q1 2026) to $3.6M (Q1 2025).